Peptide LibrarySecretin
Secretin is an FDA-approved gastrointestinal hormone in the Secretin Receptor Agonist class. Secretin is released by duodenal S cells in response to acid and binds the secretin receptor on pancreatic ductal cells, raising cyclic AMP and driving bicarbonate-rich fluid secretion that neutralises gastric acid.
For research use only.
Key Facts
- CAS
- 1393-25-5
- Molecular Weight (MW)
- 3056.4 g/mol
- Half-life
- —
- FDA status
- Approved
- FDA compounding lists
- 503A Category 3
- Evidence level
- FDA Approved
- Human dose established
- Yes
- Administration Route
- Intravenous
- Frequency
- Single injection per test
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
Research summary
Synthetic human 27-amino-acid gastrointestinal hormone approved as a diagnostic agent to stimulate pancreatic secretions, to stimulate gastrin secretion in suspected gastrinoma, and to aid identification of the ampulla during endoscopy.
Research evidence
- Regulatory review (FDA label)3 reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Secretin profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Secretin dosage evidence
Secretin has an FDA-approved human dosage only as a diagnostic agent. ChiRhoStim (human secretin) is a single intravenous injection over 1 minute: 0.2 mcg/kg to stimulate pancreatic secretions for pancreatic function testing or to find the ampulla during ERCP, and 0.4 mcg/kg to stimulate gastrin release when testing for gastrinoma.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.2–0.4 mcg/kg once, intravenously, by test |
| Route | Intravenous |
| Frequency | Single injection per test |
| Duration studied | Single use |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — ChiRhoStim, pancreatic function testingFDA-approved label · FDA prescribing information | Patients being tested for pancreatic exocrine dysfunction | 0.2 mcg/kg | Intravenous over 1 minute | Once, followed by timed duodenal fluid collection | Single dose | Stimulated pancreatic bicarbonate secretion for diagnosis | CHIRHOSTIM (human secretin) for injection — FDA prescribing information, DailyMed |
| FDA label — ChiRhoStim, gastrinoma testingFDA-approved label · FDA prescribing information | Patients being tested for gastrinoma, after a 12-hour fast | 0.4 mcg/kg | Intravenous over 1 minute | Once, with blood samples at 1, 2, 5, 10 and 30 minutes | Single dose | Stimulated gastrin release for diagnosis | CHIRHOSTIM (human secretin) for injection — FDA prescribing information, DailyMed |
| FDA label — ChiRhoStim, ERCPFDA-approved label · FDA prescribing information | Patients having ERCP when the ampulla of Vater or accessory papilla is hard to identify | 0.2 mcg/kg | Intravenous over 1 minute | Once | Single dose | Visible pancreatic fluid to identify the papillae | CHIRHOSTIM (human secretin) for injection — FDA prescribing information, DailyMed |
Where sources disagree
- Secretin's only approved uses are diagnostic tests given by clinicians. No label gives a repeated or treatment dose.
- ChiRhoStim is a synthetic human secretin powder reconstituted to 2 mcg/mL before injection. Porcine secretin products are not listed on DailyMed as of this review.
Sequence & molecular data
| Molecular formula | C130H219N43O42 |
|---|---|
| Molecular weight | 3056.4 g/mol |
| CAS number | 1393-25-5 |
| PubChem CID | 16129665 |
| FDA UNII | 88C55N56UU |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Secretin is released by duodenal S cells in response to acid and binds the secretin receptor on pancreatic ductal cells, raising cyclic AMP and driving bicarbonate-rich fluid secretion that neutralises gastric acid. In gastrinoma the normal inhibitory response is reversed and gastrin paradoxically rises, which is what the diagnostic test detects.
Studies
- Secretin modulates appetite via brown adipose tissue-brain axis
- A phase II trial of human secretin infusion for refractory type B pain in chronic pancreatitis
- Pleiotropic Effects of Secretin: A Potential Drug Candidate in the Treatment of Obesity?
- Functional Role of the Secretin/Secretin Receptor Signaling During Cholestatic Liver Injury
- Distribution and Functional Implication of Secretin in Multiple Brain Regions
Research statistics
6,854 PubMed publications · 25.6% human clinical research · 37 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Secretin is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
FDA compounding status
These FDA lists track substances nominated for use in pharmacy compounding. Being on a list is not FDA approval and doesn't mean a product is safe or effective.
| 503A Category 3 | Nominated without adequate support FDA source |
|---|
FDA list dated May 14, 2026.
How FDA approval, compounding and research-only status differ
Benefits
—
Secretin side effects
No side effects listed yet for this entry.
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Secretin: frequently asked questions
What is Secretin?
Synthetic human 27-amino-acid gastrointestinal hormone approved as a diagnostic agent to stimulate pancreatic secretions, to stimulate gastrin secretion in suspected gastrinoma, and to aid identification of the ampulla during endoscopy.
How does Secretin work?
Secretin is released by duodenal S cells in response to acid and binds the secretin receptor on pancreatic ductal cells, raising cyclic AMP and driving bicarbonate-rich fluid secretion that neutralises gastric acid. In gastrinoma the normal inhibitory response is reversed and gastrin paradoxically rises, which is what the diagnostic test detects.
Is Secretin FDA approved?
Yes. Secretin is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product. FDA's compounding lists show 503A Category 3: Nominated without adequate support.
What peptides are similar to Secretin?
Compounds most often compared with Secretin include Teduglutide, Linaclotide, Plecanatide and Larazotide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Secretin modulates appetite via brown adipose tissue-brain axis — Eur J Nucl Med Mol Imaging, 2023External reference
- A phase II trial of human secretin infusion for refractory type B pain in chronic pancreatitis — Pancreas, 2013External reference
- Pleiotropic Effects of Secretin: A Potential Drug Candidate in the Treatment of Obesity? — Front Endocrinol (Lausanne), 2021External reference
- Functional Role of the Secretin/Secretin Receptor Signaling During Cholestatic Liver Injury — Hepatology, 2020External reference
- Distribution and Functional Implication of Secretin in Multiple Brain Regions — J Mol Neurosci, 2019External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Secretin profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Secretin research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →